Investor Centre Latest shares, news and up to date company announcements IHL has commenced the full drug discovery process for cannabinoid products for OSA, TBI, SAARDS & TMJD

Welcome To Our Investor Centre

Welcome to the Investor Centre. This section is dedicated to the latest company information to our existing and prospective investors. This includes ASX announcements, financial reports, and other important updates. Investors can also access FAQs and view the latest share price information here.

*All displayed share data on this website has a 20 minutes delay

Investor Information

Investor Inquiries

For investor related enquiries please contact:
Investor Relations
Brad Dilkes
Phone: +61 (0) 422 180 317

For media related enquiries please contact:

Chief Executive Officer
Joel Latham

Key Statistics


Day high:

Day low:

Daily volume:



Number of shares:

*All displayed share data on this website has a 20 minutes delay

Incannex trades on the Australian Securities Exchange (ASX) under the ticker code IHL.

Board & Management



About Troy

Troy Valentine is a finance professional with managerial and Board experience spanning over 25 years. Originally from Perth, Troy began his career with Hartley Poynton in 1994, before moving to Patersons Securities in 2000 where he was appointed associate director of private clients. Mr Valentine has significant corporate advisory and capital raising experience, specifically with small to mid-cap size companies, and is currently co-founder and director of the boutique corporate advisory group Alignment Capital, based in Melbourne.


CEO and Managing Director

About Joel

Joel Latham is the CEO and Managing Director of Incannex Healthcare and is responsible for the Company’s commercial operations. Mr Latham is widely experienced in management and operational matters, having over 13 years’ experience in management in multiple major blue-chip organisations.

Prior to his appointment to CEO and Managing Director, Joel was the General Manager of Impression Healthcare for three years. During this time, he was instrumental negotiation and procurement of many contracts and collaborations, including with Cannvalate, AFL and NRL.


Chief Medical Officer and Director

About Dr Agarwal

Dr Agarwal is the Chief Medical Officer of Impression Healthcare, responsible for strategic decision-making and oversight over the Company’s cannabinoid clinical program and pipeline of proprietary products.

Dr Agarwal is a qualified anaesthetist and is considered one of the most influential people in the medicinal cannabis sector, as evidenced by being a recent keynote speaker at the World Cannabis Congress (held in Canada).

He is also the current CEO of Cannvalate Pty Ltd, which is Australia’s largest distributor of medicinal cannabis products. Before Impression Healthcare, Sud was the Medical Director of ASX-listed, Cann Group Limited.



About Peter

Peter Widdows is a Chartered Accountant with deep experience in all functions of business.Peter has over 17 years of experience in senior global executive positions at H.J. Heinz Corporation. He was the CEO and Managing Director of H.J. Heinz Company Australia between February 2003 and October 2008. During his tenure, Heinz Australia sales trebled, and the net profit grew by over 5 time. Following his role in Australia, he moved into a regional CEO role covering Australasia and a large part of Asia, with responsibility for 18,500 employees and revenues of US$1.8B.


Company Secretary

About Glenn

Glenn Fowles has 30 years’ experience in accounting, compliance and funds management and has been a Company Director and Company Secretary for multiple ASX listed companies in recent years.

Most notably, Mr Fowles spent 17 years at Contango Asset Management Ltd in which he had numerous roles including executive director, COO and Company Secretary. Prior to that, Glenn was the Chief Operating Officer and Executive Director of HSBC Asset Management.

ASX Announcements & Media News

29 Jan 2020 Impression Healthcare prepares for obstructive sleep apnoea clinical trial View
22 Oct 2019 Conclusion of Impression’s Agreement with ONE Championship View
04 Oct 2019 Incannex Presentation – Dr Sud Agarwal – CMO View
04 Oct 2019 CEO and Managing Director AGM Speech View
04 Oct 2019 Impression Files Patent over IHL-216A Cannabidiol Drug for Patient Administration Post Traumatic Brain Injury View